Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA

ESMO Open. 2021 Feb;6(1):100041. doi: 10.1016/j.esmoop.2020.100041. Epub 2021 Jan 18.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Humans
  • Lung
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-ret / genetics
  • Pyrazoles
  • Pyridines
  • Thyroid Neoplasms* / drug therapy
  • Thyroid Neoplasms* / genetics

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • selpercatinib
  • Proto-Oncogene Proteins c-ret
  • RET protein, human